FDA Approves Lilly's Olumiant for Pediatric Alopecia Areata
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's Olumiant (baricitinib) for the treatment of severe alopecia areata in pediatric patients aged 12 and older.
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of pediatric patients aged 12 and older with severe alopecia areata. This approval expands the U.S. label for Olumiant, which is already used for adults with moderately to severely active rheumatoid arthritis and severe alopecia areata.
Alopecia areata is a chronic autoimmune disease causing unpredictable hair loss. It affects up to 2% of the population, with nearly 40% of cases starting before age 20. Early-onset alopecia areata can be more severe and lead to extensive hair loss, significantly impacting adolescents during a critical stage of life.
The FDA's decision is based on data from the BRAVE-AA-PEDS study, the first and largest Phase 3 trial specifically designed for pediatric patients with severe alopecia areata. The 36-week results showed that Olumiant treatment led to substantial scalp hair regrowth and improvements in eyebrow and eyelash coverage compared to placebo.
The safety profile observed in the pediatric patients is consistent with that in adults. Lilly stated that this expanded approval provides a much-needed treatment choice for young people suffering from severe alopecia areata, addressing a significant unmet need in this age group.